Physician profile
Ashley Rhye
NPI 1669039194
$4,498.10
in general payments reported to CMS, 2019-2025
44 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $674 · 2023: $773 · 2024: $1,290 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $572.48 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $325.56 | 2023-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $315.23 | 2021-2025 | Talvey, Darzalex, Balversa |
| Celgene Corporation | $275.23 | 2021-2025 | Reblozyl, Opdualag |
| Incyte Corporation | $195.74 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Beigene USA, INC. | $184.18 | 2021-2025 | Brukinsa |
| Pfizer INC. | $175.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $170.19 | 2021-2025 | Keytruda, Lynparza |
| Exelixis INC. | $147.17 | 2021-2024 | Cabometyx |
| Daiichi Sankyo INC. | $142.64 | 2023-2025 | Enhertu, Datroway |
| Eisai INC. | $140.76 | 2021-2024 | |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Takeda Pharmaceuticals U.S.A., INC. | $112.25 | 2022-2025 | Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $109.82 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Pharmacyclics LLC, An Abbvie Company | $109.76 | 2022-2023 | Imbruvica |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $101.38 | 2024-2025 | |
| Array Biopharma INC | $97.04 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Amgen INC. | $91.30 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $90.24 | 2023-2025 | Somatuline Depot, Onivyde |
| Abbvie INC. | $85.81 | 2023-2025 | |
| Seagen INC. | $85.61 | 2022-2023 | Tukysa, Tivdak, Adcetris |
| Beone Medicines USA, INC. | $80.94 | 2025 | Brukinsa, Tevimbra |
| Pharmacosmos Therapeutics INC. | $71.42 | 2024-2025 | Monoferric, Cosela |
| Astrazeneca Pharmaceuticals LP | $70.60 | 2021-2025 | Imfinzi, Calquence |
| Alexion Pharmaceuticals, INC. | $65.26 | 2024 | Soliris, Ultomiris |
| Stemline Therapeutics INC. | $58.48 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $51.53 | 2025 | Polivy, Phesgo |
| Genzyme Corporation | $49.36 | 2021-2024 | |
| Mirati Therapeutics, INC. | $41.76 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.62 | 2025 | |
| Lilly USA, LLC | $36.43 | 2021-2022 | |
| Adc Therapeutics America, INC. | $35.78 | 2022-2023 | |
| Astellas Pharma US INC | $28.89 | 2022-2025 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $27.54 | 2022 | |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Sun Pharmaceutical Industries INC. | $21.02 | 2025 | |
| Karyopharm Therapeutics INC. | $18.84 | 2022 | |
| Genmab U.S., INC. | $18.05 | 2025 | Epkinly |
| Kyowa Kirin, INC. | $17.62 | 2025 | |
| Servier Pharmaceuticals LLC | $16.99 | 2024 | |
| Taiho Oncology, INC. | $16.90 | 2024 | |
| Sobi, INC | $15.46 | 2023 | |
| Global Blood Therapeutics, INC. | $15.02 | 2022 | |
| Kite Pharma, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rhye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.